Injecting Drug Use History and Younger Age Worsen Adherence to Scheduled Hospital Visits in Glecaprevir and Pibrentasvir Therapy for Chronic Hepatitis C

Benzer Materyaller

• Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide
  Yazar:: Aleksandra Berkan-Kawińska, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-07-01)
• Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve, Compensated Cirrhotic HCV Patients
  Yazar:: Nancy Reau, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-06-01)
• Safety and effectiveness of 8 weeks of Glecaprevir/Pibrentasvir in challenging HCV patients: Italian data from the CREST study.
  Yazar:: Alessio Aghemo, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-01-01)
• The experience of the Moscow City Center for AIDS Prevention and Treatment of using glecaprevir/pibrentasvir in patients with HIV/HCV coinfection
  Yazar:: A. I. Mazus, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-12-01)
• Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study
  Yazar:: Marianne Martinello, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-10-01)